The only significant variations observed were for quality 3 or higher neutropenia and exhaustion . During a median 35.2 months of follow-up, 87 individuals died. The risk of death was non-significantly lower in the in the concurrent arm compared with the sequential arm, at an unadjusted hazard ratio of 0.92 and median overall survival moments of 24.3 and 18.4 months, respectively. Individuals who received concurrent treatment were slightly less inclined to end up being alive at 12 months but slightly more likely to be alive at 24 months compared with those that received sequential treatment; the particular 1 – and 2 – 12 months overall survival rates were 70 percent versus 83 percent and 50 percent versus 46 percent.Despite the fact that high degrees of minimal residual disease (i.e. Indeed, although patients with degrees of minimal residual disease between 0.01 and 0.99 percent had a cumulative threat of relapse of 43 percent in our previous trials,15 patients with the same levels had a 5-year event-free survival rate of 79.5 percent in this study. Vigilant supportive care led to a rate of death from toxic effects of only one 1.4 percent, despite intensive treatment. Rates of disseminated fungal infection and thrombosis were considerable, but no affected individual died of these complications. Severe infection, osteonecrosis, thrombosis, and hyperglycemia had been more likely to build up in children over the age of 10 years old than in younger patients; this finding may be described by slower clearance of dexamethasone in older patients.